Skip to main content
. 2020 Aug 19;9(9):2682. doi: 10.3390/jcm9092682

Table 1.

First and subsequent second-line therapies.

1st Line # (%) 2nd Line # (%)
Sorafenib/Lenvatinib 88 (89.8) Nivolumab 33 (37.5)
Pembrolizumab 8 (9.1)
Regorafenib 18 (20.5)
Cabozantinib 20 (22.7)
Ramucirumab 9 (10.2)
Nivolumab 10 (10.2) Sorafenib (100%) 10 (100)